Rhythm Pharmaceuticals/$RYTM
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Ticker
$RYTM
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
283
ISIN
US76243J1051
Website
RYTM Metrics
BasicAdvanced
$5.8B
-
-$2.82
2.30
-
Price and volume
Market cap
$5.8B
Beta
2.3
52-week high
$94.80
52-week low
$40.61
Average daily volume
814K
Financial strength
Current ratio
3.302
Quick ratio
2.972
Long term debt to equity
68.535
Total debt to equity
69.647
Interest coverage (TTM)
-12.47%
Profitability
EBITDA (TTM)
-263.479
Gross margin (TTM)
89.62%
Net profit margin (TTM)
-123.28%
Operating margin (TTM)
-193.64%
Effective tax rate (TTM)
-0.07%
Revenue per employee (TTM)
$480,000
Management effectiveness
Return on assets (TTM)
-51.33%
Return on equity (TTM)
-150.20%
Valuation
Price to revenue (TTM)
40.156
Price to book
298.39
Price to tangible book (TTM)
435.33
Price to free cash flow (TTM)
-48.215
Free cash flow yield (TTM)
-2.07%
Free cash flow per share (TTM)
-184.67%
Growth
Revenue change (TTM)
48.88%
Earnings per share change (TTM)
-39.75%
3-year revenue growth (CAGR)
209.49%
3-year earnings per share growth (CAGR)
-5.16%
10-year earnings per share growth (CAGR)
19.97%
What the Analysts think about RYTM
Analyst ratings (Buy, Hold, Sell) for Rhythm Pharmaceuticals stock.
Bulls say / Bears say
Rhythm Pharmaceuticals successfully raised $175 million through an upsized public offering at $85 per share, strengthening its financial position for rare disease drug commercialization efforts. (stocktitan.net)
The company announced that its oral MC4R agonist, Bivamelagon, achieved statistically significant and clinically meaningful BMI reductions in a Phase 2 trial for acquired hypothalamic obesity, indicating potential for future regulatory approvals. (stocktitan.net)
Analysts have shown confidence in Rhythm Pharmaceuticals, with Canaccord Genuity Group raising their price target from $81.00 to $92.00 and maintaining a buy rating. (marketbeat.com)
Rhythm Pharmaceuticals reported a quarterly loss of $0.72 per share, missing the consensus estimate by $0.03, indicating ongoing financial challenges. (tickerreport.com)
The company has a negative net margin of 230.07% and a negative return on equity of 367.36%, reflecting significant operational inefficiencies. (tickerreport.com)
Despite positive trial results, the path to regulatory approval and successful commercialization of new treatments remains uncertain and could face delays. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
RYTM Financial Performance
Revenues and expenses
RYTM Earnings Performance
Company profitability
RYTM News
AllArticlesVideos
Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock
GlobeNewsWire·1 day ago
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
GlobeNewsWire·2 days ago
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity
GlobeNewsWire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rhythm Pharmaceuticals stock?
Rhythm Pharmaceuticals (RYTM) has a market cap of $5.8B as of July 11, 2025.
What is the P/E ratio for Rhythm Pharmaceuticals stock?
The price to earnings (P/E) ratio for Rhythm Pharmaceuticals (RYTM) stock is 0 as of July 11, 2025.
Does Rhythm Pharmaceuticals stock pay dividends?
No, Rhythm Pharmaceuticals (RYTM) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Rhythm Pharmaceuticals dividend payment date?
Rhythm Pharmaceuticals (RYTM) stock does not pay dividends to its shareholders.
What is the beta indicator for Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals (RYTM) has a beta rating of 2.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.